Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Melinta: A Pure-Play Antibiotics Specialist Rises

Executive Summary

CEO Daniel Wechsler talked with Scrip about being a pure-play specialist in the challenging antibiotics market, following the acquisition of The Medicines Co.'s anti-infectives franchise and a reverse merger with Cempra last year.

Advertisement

Related Content

Commercial, Reimbursement Hurdles Need To Be Addressed By Antimicrobial Resistance Efforts
Commercial, Reimbursement Hurdles Need To Be Addressed By Antimicrobial Resistance Efforts
REPAIR Is Trying To Fix The Antibiotic Gap Left By Industry
Finance Watch: Six More IPO Filings As Three More Biopharmas Go Public In The US
Melinta Expands Portfolio, TMC Narrows Focus To LDL Reduction With Anti-Infective Deal
US Approval Of Vabomere Could Help Alleviate TMC's Financial Troubles
Merger With Cempra Takes Melinta Public, Will Help Launch Baxdela
Melinta To Launch First Commercial Drug Baxdela Independently

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100254

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel